Front Row Advisors LLC Biogen Inc. Transaction History

Front Row Advisors LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Mar 09, 2022	SELL	$223.92 - $287.77 $6,717 - $8,633	-30 Closed	0 $0
Q3 2020 Nov 30, 2020	SELL	$264.77 - $305.71 $5,824 - $6,725	-22 Reduced 42.31%	30 $7,000
Q2 2020 Aug 17, 2020	SELL	$258.66 - $342.55 $24,314 - $32,199	-94 Reduced 64.38%	52 $14,000
Q1 2020 May 08, 2020	SELL	$268.85 - $341.04 $3,226 - $4,092	-12 Reduced 7.59%	146 $43,000
Q4 2019 Feb 14, 2020	BUY	$220.06 - $304.07 $23,766 - $32,839	108 Added 216.0%	158 $47,000
Q3 2019 Nov 08, 2019	SELL	$217.44 - $243.88 $1,739 - $1,951	-8 Reduced 13.79%	50 $12,000
Q2 2019 Aug 27, 2019	BUY	$219.29 - $241.72 $1,973 - $2,175	9 Added 18.37%	58 $14,000
Q1 2019 May 17, 2019	SELL	$216.71 - $338.96 $653,380 - $1.02 Million	-3,015 Reduced 98.4%	49 $12,000
Q4 2018 Feb 13, 2019	SELL	$278.5 - $352.75 $12,532 - $15,873	-45 Reduced 1.45%	3,064 $922,000
Q3 2018 Nov 13, 2018	BUY	$293.51 - $383.83 $16,143 - $21,110	55 Added 1.8%	3,109 $939,000
Q2 2018 Jul 31, 2018	BUY	$257.52 - $306.91 $51,246 - $61,075	199 Added 6.97%	3,054 $1.17 Million
Q1 2018 May 21, 2018	BUY	$260.13 - $367.91 $61,130 - $86,458	235 Added 8.97%	2,855 $782,000
Q4 2017 Feb 01, 2018	BUY	$307.64 - $344.58 $806,016 - $902,799	2,620	2,620 $835,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Front Row Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Front Row Advisors LLC with notifications on news.